Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation

CompletedOBSERVATIONAL

Enrollment

87,810

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions

Atrial Fibrillation

Interventions

DRUG

dronedarone

Pharmaceutical form is tablet and route of administration is oral

DRUG

sotalol

Pharmaceutical form is tablet and route of administration is oral

Trial Locations (1)

Sanofi-Aventis, France, Chilly-Mazarin